Evidently, within the medical device sector influenced by various market and policy factors, ophthalmic surgical microscopes have emerged as one of the most resilient and strongly growing sub-segments in China. While the increase in winning bid volume for these devices is partly driven by rising surgical demand, from a product perspective, why are ophthalmic surgical microscopes selling so well?

More than betting on a specific device, investors are backing the increasingly evident trend that Synaire aims to address: in modern society, quality sleep is becoming a luxury, yet the nighttime needs of the vast majority of people still lack truly effective solutions.

Most people know Biocytogen as a leading model animal supplier in China. Around 2021, laboratory mice used in preclinical drug research suddenly became scarce and highly sought after, which brought Biocytogen and its two peers, GemPharmatech and Shanghai Model Organisms Center, into the spotlight. To this day, selling target-humanized model mice remains Biocytogen's primary revenue source.

To rapidly enter the small nucleic acid field, Innovent initiated a collaboration with SanegeneBio on December 27, 2023, to co-develop SGB-3908, a small nucleic acid candidate for hypertension. Innovent's technological roadmap has also continuously expanded, evolving from early-stage monoclonal and bispecific antibodies to ADCs and fusion proteins, and now venturing into small nucleic acids.

A striking contrast is unfolding in the cardiac valve market: Chinese domestic cardiac valve manufacturers have firmly dominated the local TAVR (Transcatheter Aortic Valve Replacement) market, collectively holding approximately 80% of the market share. On the other hand, the revenue of China's leading cardiac valve companies lags behind that of international valve giants by over RMB 20 billion.

Under the terms of the agreement, Kelun-Biotech has granted Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 in the United States, Europe, and all markets outside of Greater China. In turn, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001 in Greater China.

It is reported that the NeuViz 1024 is equipped with a high-definition imaging chain ranging from the detector to the reconstruction algorithm, featuring an ultra-thin slice thickness of 0.3125 mm. The system achieves a spatial resolution of up to 46.5 lp/cm (compared to the 40 lp/cm spatial resolution publicly stated for the Canon photon-counting CT TSX-501R), realizing photon-counting-level microscopic detail on a conventional energy-integrating detector platform.

As the globally first molecular glue degrader targeting HuR, DEG6498 represents a highly innovative therapeutic approach with the potential to meet high unmet need across multiple indications. HuR is an RNA-binding protein playing critical roles in driving cancer, inflammatory and metabolic disorders, and has long been considered an undruggable target. Leveraging its proprietary molecular glue degrader discovery platform and innovative approaches, Degron has successfully overcome this challenge.

The China Innovation Talk series, launched by VCBeat, aims to establish a platform for in-depth dialogue. We will go to the front lines to listen to core "game-changers" from the investment, academic, and industrial sectors as they share their cutting-edge insights, strategies for breaking through barriers, and reflections on ongoing challenges. Their voices will help us better grasp the pulse of the industry's transformation and gain a clearer vision of future opportunities and challenges.

For a long time, artificial tears, primarily sodium hyaluronate eye drops, have been favored as a "one-size-fits-all" remedy by patients with various types of dry eye due to their rapid perceived effect, over-the-counter (OTC) availability, and easy accessibility. This contributed to a market structure dominated by single blockbuster products. To this day, leading sodium hyaluronate brands continue to experience sales growth.

Currently, the number of patients with functional brain disorders, such as depression, Parkinson's disease, and autism spectrum disorder, continues to rise. Taking depression as an example, World Health Organization (WHO) data indicates that the global prevalence of depression among adults is approximately 5.7%. According to data from the Chinese Center for Disease Control and Prevention, about 95 million people in China are affected by depression.

The two parties will jointly share the global development costs for BL-B01D1 and will share profits and losses in the U.S. market. SystImmune, through its affiliates, retains the exclusive development and commercialization rights for BL-B01D1 in mainland China, and Bristol Myers Squibb will receive royalties on net sales from mainland China.

Dr. Chen's efforts are attempting to solve a long-standing challenge for China's innovative drug industry: how to ensure patient accessibility to medications while enabling companies to sustain R&D efforts (sustainability). His answer is a two-pronged strategy: internally, through technological and management innovations, production costs are minimized to create room for price reductions;

Multiple System Atrophy (MSA) is a rapidly progressive neurodegenerative disorder in adults. The disease advances aggressively, with most patients facing life-threatening risks within 6 to 10 years after diagnosis. Clinically, patients typically present with varying combinations of autonomic failure, parkinsonism, and cerebellar ataxia, resulting in a complex condition that poses significant diagnostic and therapeutic challenges.

In light of the collective partnerships between surgical robotics companies, research institutions, and NVIDIA, we must consider: Can these NVIDIA-supported surgical robots compete with the market-dominating da Vinci system? Can Chinese domestic surgical robots, which already hold a leading position in intelligence and automation, secure a significant market share in the future? What challenges remain to be overcome in realizing the future of intelligent, automated surgical robots?

As the clinical lead for establishing standards for the lymphoma AI physician, Professor Ma Jun has a clear roadmap for the development of AI in medicine. He emphasizes that standard-setting must be grounded in clinical needs, ensuring not only the technological advancement but, more critically, its usability and safety in real-world clinical settings.

This milestone establishes Fucaso® as the first China-developed CAR-T cell therapy product approved in Hong Kong, and also the first Chinese Advanced Therapy Medicinal Product (ATMP) to obtain international PIC/S GMP certification.

As a globally recognized GLP-1 receptor agonist, liraglutide's core indication is glycemic control in patients with type 2 diabetes, and it can be used as monotherapy or in combination with other antidiabetic agents to improve blood glucose levels.

According to the IDF Diabetes Atlas 2025, approximately 89.83 million adults aged 20-79 in India have diabetes, representing a prevalence rate of 9.5%, ranking the country second globally in the number of people affected. India also faces the highest number of diabetes-related deaths worldwide.

The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.